
Marlieke de Kraker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7614134/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050?. PLoS Medicine, 2016, 13, e1002184.	8.4	929
2	Mortality and Hospital Stay Associated with Resistant Staphylococcus aureus and Escherichia coli Bacteremia: Estimating the Burden of Antibiotic Resistance in Europe. PLoS Medicine, 2011, 8, e1001104.	8.4	472
3	Attributable Mortality of Ventilator-Associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1133-1139.	5.6	330
4	Surveillance for control of antimicrobial resistance. Lancet Infectious Diseases, The, 2018, 18, e99-e106.	9.1	235
5	Clinical Impact of Antimicrobial Resistance in European Hospitals: Excess Mortality and Length of Hospital Stay Related to Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infections. Antimicrobial Agents and Chemotherapy, 2011, 55, 1598-1605.	3.2	226
6	Ventilator-Associated Events. Critical Care Medicine, 2015, 43, 1798-1806.	0.9	120
7	Impact of the COVID-19 pandemic on the surveillance, prevention and control of antimicrobial resistance: a global survey. Journal of Antimicrobial Chemotherapy, 2021, 76, 3045-3058.	3.0	88
8	Attributable mortality of ventilator-associated pneumonia. Current Opinion in Critical Care, 2011, 17, 464-471.	3.2	78
9	Update on ventilator-associated pneumonia. F1000Research, 2017, 6, 2061.	1.6	78
10	Does Catheter-Associated Urinary Tract Infection Increase Mortality in Critically Ill Patients?. Infection Control and Hospital Epidemiology, 2007, 28, 1367-1373.	1.8	73
11	Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE's STAT-Net. Intensive Care Medicine, 2017, 43, 1002-1012.	8.2	44
12	Treatment of severe hospital-acquired and ventilator-associated pneumonia: a systematic review of inclusion and judgment criteria used in randomized controlled trials. Critical Care, 2017, 21, 162.	5.8	34
13	Implementation of hand hygiene in health-care facilities: results from the WHO Hand Hygiene Self-Assessment Framework global survey 2019. Lancet Infectious Diseases, The, 2022, 22, 835-844.	9.1	29
14	Comparison of Routine Replacement With Clinically Indicated Replacement of Peripheral Intravenous Catheters. JAMA Internal Medicine, 2021, 181, 1471.	5.1	26
15	Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials. Clinical Infectious Diseases, 2019, 69, 1912-1918.	5.8	24
16	Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper From COMBACTE's STAT-Net. Clinical Infectious Diseases, 2018, 67, 1922-1931.	5.8	23
17	Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial. Critical Care, 2021, 25, 290.	5.8	21
18	Methodological quality of studies evaluating the burden of drug-resistant infections in humans due to the WHO Global Antimicrobial Resistance Surveillance System target bacteria. Clinical Microbiology and Infection, 2021, 27, 687-696.	6.0	19

#	Article	IF	CITATIONS
19	Study protocol for a multicentre, cluster randomised, superiority trial evaluating the impact of computerised decision support, audit and feedback on antibiotic use: the COMPuterized Antibiotic Stewardship Study (COMPASS). BMJ Open, 2018, 8, e022666.	1.9	11
20	Shining a light on ultraviolet-C disinfection: No golden promises for infection prevention. American Journal of Infection Control, 2018, 46, 1422-1423.	2.3	5
21	Estimation of adjusted expected excess lengthâ€ofâ€stay associated with ventilationâ€acquired pneumonia in intensive care: A multistate approach accounting for timeâ€dependent mechanical ventilation. Biometrical Journal, 2018, 60, 1135-1150.	1.0	5
22	The Impact of Early Adequate Treatment on Extubation and Discharge Alive of Patients With Pseudomonas aeruginosa-Related Ventilator-Associated Pneumonia*. Critical Care Medicine, 2018, 46, 1643-1648.	0.9	4
23	Mortality attributable to third-generation cephalosporin resistance in Gram-negative bloodstream infections in African hospitals: a multi-site retrospective study. JAC-Antimicrobial Resistance, 2021, 3, dlaa130.	2.1	4
24	Mortality associated with third-generation cephalosporin resistance in Enterobacteriaceae bloodstream infections at one South African hospital. Journal of Global Antimicrobial Resistance, 2022, 29, 176-184.	2.2	4
25	HAP and VAP after Guidelines. Seminars in Respiratory and Critical Care Medicine, 2022, 43, 248-254.	2.1	3